AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

BLLN · NASDAQ · Medical - Diagnostics & Research

BillionToOne (BLLN)

Develops molecular diagnostics for prenatal screening and cancer treatment selection.

$115.43

vs last close−0.64 (−0.55%)

In millions of USD, except per-share figures

In millions	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	33	36	38	45	59	67	84	96	108	109
Cost of revenue	16	18	18	19	21	23	25	27	29	32
Gross profit	16	19	20	26	38	43	58	69	79	77
	28	30	33	37	40	45	49	58	61	72
Research & development	7	9	10	11	10	12	13	14	15	17
Selling, general & administrative	20	21	23	26	30	33	36	44	47	54
Operating income	−11	−12	−13	−12	−2	−2	10	10	18	6
	−1	8	−2	0	−2	1	−4	−4	1	2
Interest income	1	1	2	2	2	1	2	3	5	5
Interest expense	1	1	0	0	0	0	0	0	0	0
Other non-operating income	0	−9	2	0	2	−1	4	4	−1	−2
Income before tax	−12	−3	−15	−11	−4	0	6	6	19	8
Income tax expense	0	0	0	0	0	0	0	0	1	−1
Net income from continuing operations	−12	−3	−15	−11	−4	0	6	6	18	8
Other adjustments	0	0	0	0	0	0	−4	0	0	0
Net income	−12	−3	−15	−11	−4	0	2	6	18	8
EPS, basic	−$0.27	−$0.07	−$0.33	−$0.26	−$0.09	−$0.01	$0.03	$0.10	$0.39	$0.17
EPS, diluted	−$0.27	−$0.07	−$0.33	−$0.26	−$0.09	−$0.01	$0.03	$0.10	$0.34	$0.15
Weighted average shares, basic	45	45	45	45	45	45	45	46	46	46
Weighted average shares, diluted	45	45	45	45	45	45	45	46	53	54
EBITDA	−9	−1	−13	−10	−2	2	9	9	22	11
Depreciation & amortization	2	2	2	2	2	2	3	3	3	3
EBIT	−11	−2	−14	−11	−4	0	6	6	19	8